Prostate Cancer Reclassification Linked to Low Testosterone

Share this content:
Prostate Cancer Reclassification Linked to Low Testosterone
Prostate Cancer Reclassification Linked to Low Testosterone

(HealthDay News) -- Men under active surveillance for prostate cancer who have reductions in testosterone levels may be at increased risk for disease reclassification, according to research published online May 4 in BJU International.

Ignacio F. San Francisco, MD, of the Pontificia Universidad Catolica de Chile, Santiago, and colleagues analyzed data from a cohort of 154 men on active surveillance for prostate cancer to assess the association between testosterone levels and risk of disease reclassification.

RELATED: Male Reproductive Cancers Resource Center

The researchers found that patients who had disease that was reclassified, compared with those who did not, had significantly lower levels of free testosterone (0.75 ng/dL vs. 1.02 ng/dL; P = 0.03). A higher rate of reclassification of disease was observed in patients with free testosterone levels <0.45 ng/dL than in those with levels ≥0.45 ng/dL (P = 0.032). 

Patients with free testosterone levels <0.45 ng/dL were at increased risk of disease reclassification (odds ratio, 4.3; 95% confidence interval, 1.25 to 14.73). Independent predictors of disease reclassification included free testosterone level and family history of prostate cancer.

"Men with moderately severe reductions in free testosterone level are at increased risk of disease reclassification," the researchers wrote.

Reference

  1. San Francisco IF, Rojas PA, DeWolf WC, et al. Low free testosterone levels predict disease reclassification in men with prostate cancer undergoing active surveillance. BJU Int. 2014;doi:10.1111/bju.12682.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs